Download Error - Wiley

Supplementary Table 1. Genes regulated by hnRNP A2 and their association with
cancer
Gene Symbol
Fold
change
Gene Title
Membrane Effects
Cytoskeletal structure/Cytoskeletal interactions
KRT13
2.55 Keratin 13
Reference
sequence
Aberrant alteration in cancer
Oncogene or References
tumour
suppressor
KRT15
1.60
Keratin 15
NM_002274 Downregulated in squamous cell
carcinoma
NM_002275
KRT6B
2.55
Keratin 6B
NM_005555
SPRR1A
3.48
Small proline-rich protein 1A
[2]
SPRR1B
3.14
SPRR2A
2.38
Small proline-rich protein 1B
(cornifin)
Small proline-rich protein 2A
NM_005987 Downregulated in squamous cell
carcinoma
NM_003125 Downregulated in gastric cancer
[2]
SPRR3
4.07
Small proline-rich protein 3
NM_005988 Downregulated in squamous cell
carcinoma
NM_005416 Downregulated in squamous cell
carcinoma
NM_025135
FHOD3
-1.30 Formin homology 2 domain
containing 3
FLNB
1.37 Filamin B, beta (actin binding protein
278)
Cell adhesion and motility
CEACAM5
1.90 Carcinoembryonic antigen-related cell
adhesion molecule 5
CEACAM6
1.90 Carcinoembryonic antigen-related cell
adhesion molecule 6
CTNND1
1.65 Catenin (cadherin-associated protein),
delta 1
DCBLD2
-2.08 Discoidin, CUB and LCCL domain
containing 2
MCAM
-1.59 Melanoma cell adhesion molecule
Oncogene
[4]
NM_002483 Upregulated in many cancer
Oncogene
[4,5]
NM_001331 Downregulated in colon cancer
Oncogene
[6,7]
NM_080927 Upregulated in lung cancer
1.52
Solute carrier family 7, member 8
NM_012244
FXYD3
1.74
CLDN4
1.52
FXYD domain containing ion
transport regulator 3
Claudin 4
FER1L3
1.37
Fer-1-like 3, myoferlin (C. elegans)
NM_005971 Upregulated in prostate and
pancreatic cancer
NM_001305 Upregulated in ovarian cancerr
Downregulated in gastric cancer
NM_013451
TMEM16A
-1.69 Transmembrane protein 16A
TMEM45A
1.60
TMEM109
-1.54 Transmembrane protein 109
NM_018043 Upregulated in squamous cell
carcinoma
NM_018004
MCFD2
CALML3
[8]
Tumour
suppressor
Tumour
suppressor
Tumour
suppressor
[9,10]
[11]
[12,13]
[14,15]
[16]
NM_024092
Calcium-binding proteins
S100A12
1.87 S100 calcium binding protein A12
(calgranulin C)
S100A14
1.62 S100 calcium binding protein A14
S100P
[2]
NM_004363 Upregulated in many cancer
SLC7A8
S100A8
[3]
NM_001457
NM_006500 Upregulated in melanoma and
prostate cancer
FAT
1.54 FAT tumor suppressor homolog 1 (D. NM_005245 Upregulated in breast carcinoma
melanogaster)
THBS1
-1.39 Thrombospondin 1
NM_003246 Upregulated in lung, breast, and
gastrointestinal cancer
AAMP
1.37 Angio-associated, migratory cell
NM_001087
protein
Integral to plasm membrane
AQP3
2.78 Aquaporin 3
NM_004925
Transmembrane protein 45A
[1]
NM_005621 Downregulated in squamous cell
carcinoma
NM_020672 Downregulated in squamous cell
carcinoma
2.38 S100 calcium binding protein A8
NM_002964 Downregulated in squamous cell
(calgranulin A)
carcinoma
3.19 S100 calcium binding protein P
NM_005980 Downregulated in squamous cell
carcinoma
-1.56 Multiple coagulation factor deficiency NM_139279
2
1.57 Calmodulin-like 3
NM_005185 Downregulated in breast cancer
39
[17]
[17]
[17]
[17]
[18]
Metabolism
AKR1A1
1.30
AKR1C1
1.97
AKR1C2
1.80
AKR1C3
2.30
IDH1
1.46
FDFT1
1.44
SC4MOL
1.54
CYP1A1
1.97
Aldo-keto reductase family 1, member
A1
Aldo-keto reductase family 1, member
C1
Aldo-keto reductase family 1, member
C2
Aldo-keto reductase family 1, member
C3
Isocitrate dehydrogenase 1 (NADP+),
soluble
Farnesyl-diphosphate
farnesyltransferase 1
Sterol-C4-methyl oxidase-like
NM_006066
NM_001353 Downregulated in prostate and
breast cancer
NM_001354 Downregulated in prostate and
breast cancer
NM_003739 Downregulated in breast tumour
[19,20]
[19,20]
[21]
NM_005896
NM_004462 Amplified in esophageal
adenocarcinoma
NM_006745
[22]
[23]
SMS
Cytochrome P450, family 1, subfamily NM_000499 Upregulated in ovarian cancer
A, polypeptide 1
1.68 UDP glycosyltransferase 1 family,
NM_000463 Downregulation in liver and
polypeptides A1, A10, A4, and A6
NM_001072 biliary cancer
NM_007120
NM_019075
1.68 Spermidine/spermine N1NM_002970
acetyltransferase
-1.85 Spermine synthase
NM_004595
MAOA
1.57
Monoamine oxidase A
NM_000240 Upregulated in prostate cancer
[25]
SCD
1.46
Stearoyl-CoA desaturase
AB032261
[26]
HMOX1
2.14
Heme oxygenase (decycling) 1
UGT1A1/
UGT1A10/
UGT1A4/
UGT1A6
SAT
Nucleic acid and protein processing
DNA binding, DNA replication and chromatin assembly
HIST1H2AC 2.14 Histone 1, H2ac
Downregulated in prostate
carcinoma
NM_002133 Upregulated in breast cancer
2.00
Histone 1, H2bd
NM_021063
HIST1H2BK
1.52
Histone 1, H2bk
NM_080593
HIST2H2AA
1.57
Histone 2, H2aa
NM_003516
PFS2
HARS
-1.79 DNA replication complex GINS
NM_016095 Upregulated in intrahepatic
protein PSF2
cholangiocarcinoma
-1.85 Apolipoprotein B mRNA editing
NM_021822
enzyme, catalytic polypeptide-like 3G
2.07 Argininosuccinate synthetase
NM_000050 Downregulated in melanoma,
hepatocellular carcinoma, and
prostate carcinoma
1.57 Histidyl-tRNA synthetase
NM_002109
SYNCRIP
1.49
ASS
[27]
NM_003512
HIST1H2BD
APOBEC3G
[24]
[28]
[29]
Synaptotagmin binding, cytoplasmic NM_006372
RNA interacting protein
WHSC1
-1.54 Wolf-Hirschhorn syndrome candidate NM_007331 Amplified in breast cancer
Oncogene
1
Transcription Factors
CEBPB
1.34 CCAAT/enhancer binding protein
NM_005194 Upregulated in gastric and wilms
(C/EBP), beta
tumours
DLX2
1.49 Distal-less homeo box 2
NM_004405 Downregulated in leukemia
IRF7
1.80
JARID1B
1.49
MLF1IP
MYBL1
Interferon regulatory factor 7
Jumonji, AT rich interactive domain
1B (RBP2-like)
-1.37 MLF1 interacting protein
PSIP1
-1.89 v-myb myeloblastosis viral oncogene
homolog (avian)-like 1
1.74 Putative homeodomain transcription
factor 2
-1.49 PC4 and SFRS1 interacting protein 1
SOX18
1.90
PHTF2
NM_001572 Upregulated in embryonic
carcinoma cells
NM_006618 Upregulated in breast cancer
[32,33]
[34]
[35]
[36]
NM_024629 Upregulated in glioblastoma
AW592266 Induced in lymphoma
[30,31]
[37]
Oncogene
[38,39]
NM_020432
NM_021144 Upregulated in prostate cancer
SRY (sex determining region Y)-box NM_018419
18
STAT1
2.07 Signal transducer and activator of
NM_007315
transcription 1, 91kDa
Intracellular protein transport/protein localization/protein processing
AKAP12
1.54 A kinase (PRKA) anchor protein
NM_005100
(gravin) 12
AP1S2
-1.52 Adaptor-related protein complex 1,
NM_003916
sigma 2 subunit
40
[40]
Downregulated and
hypermethylated in lung cancer
Downregulation in squamous cell Tumour
carcinoma
suppressor
[41]
Downregulated in prostate and
breast cancers
[44]
Tumour
suppressor
[42,43]
KDELR2
1.60
TIMM17A
2.00
TIMM17B
1.39
GABARAPL1
1.90
GABARAPL2
1.23
SAR1A
1.60
KDEL endoplasmic reticulum protein
retention receptor 2
Translocase of inner mitochondrial
membrane 17 homolog A (yeast)
Translocase of inner mitochondrial
membrane 17 homolog B (yeast)
GABA(A) receptor-associated protein
like 1
GABA(A) receptor-associated proteinlike 2
SAR1a gene homolog 1 (S. cerevisiae)
ACP1
1.41
Acid phosphatase 1, soluble
NM_006854
NM_006335
NM_005834
NM_031412
NM_007285
NM_020150
ERO1L
NM_004300 Upregulated in breast and colon
cancer
-1.45 Proteasome (prosome, macropain) 26S NM_002810 Upregulated in liver cancer
subunit, non-ATPase, 4
-1.92 S-phase kinase-associated protein 2
NM_005983 Upregulated in oral cancer
(p45)
1.37 RAB guanine nucleotide exchange
NM_014504
factor (GEF) 1
1.41 ERO1-like (S. cerevisiae)
NM_014584
TAP1
1.77
PSMD4
SKP2
RABGEF1
Transporter 1, ATP-binding cassette,
sub-family B
Peptidases/peptidase inhibitors
SERPINE1
-1.32 Serine/cysteine proteinase inhibitor,
clade E (nexin, plasminogen activator
inhibitor type 1), member 1
SERPINB2
2.14 Serine/cysteine proteinase inhibitor,
clade B (ovalbumin), member 2
SLPI
2.30 Secretory leukocyte protease inhibitor
(antileukoproteinase)
PI3
2.07 Peptidase inhibitor 3, skin-derived
(SKALP)
MMP1
1.71 Matrix metalloproteinase 1 (interstitial
collagenase)
PSEN1
1.62 Presenilin 1 (Alzheimer disease 3)
-1.39
PTTG1
-1.37
ESPL1
-1.54
MAPRE1
1.32
GTSE1
-1.52
CTGF
-2.00 Connective tissue growth factor
MKI67
-1.37 Antigen identified by monoclonal
antibody Ki-67
Apoptosis
LGALS1
TNFRSF10B
TNFRSF6B
[46]
Oncogene
[47]
[48]
NM_000602 Upregulated in breast and gastric Tumour
cancer
suppressor
[49,50]
NM_002575 Upregulated in endometrial cancer
[51]
NM_003064 Upregulated in lung and ovary
cancer
NM_002638 Upregulated in squamous cell
carcinoma
NM_002421 Upregulated in breast and
oesophageal carcinoma
NM_000021 Upregulated in lung cancer
[52,53]
NM_001759 Downregulated in breast/gastric
cancer but upregulated in some
cases of gastric cancer
TPX2, microtubule-associated protein NM_012112 Upregulated in squamous cell
homolog (X. laevis)
carcinoma
Pituitary tumor-transforming 1
NM_004219 Overexpressed in melanoma and
hepatocellular carcinoma
Extra spindle poles like 1 (S.
NM_012291
cerevisiae)
Microtubule-associated protein,
NM_012325 Upregulated in medulloblastoma
RP/EB family, member 1
G-2 and S-phase expressed 1
NM_016426
Cell growth/cell proliferation
IGFBP6
1.41 Insulin-like growth factor binding
protein 6
IGFBP7
-1.37 Insulin-like growth factor binding
protein 7
[45]
NM_000593 Downregulated in glioma
Cell growth and maintenance
Cell cycle
CCND2
2.00 Cyclin D2
TPX2
Oncogene
NM_002178 Upregulated in adrenocortical
carcinomas
NM_001553 Upregulated in mesothelioma,
breast cancer and central nervous
system tumors
NM_001901 Upregulated in breast, pancreatic
cancer
NM_002417 Upregulated in cervical, vaginal,
and vulvar carcinomas and oral
squamous cell carcinoma
-2.94 Lectin, galactoside-binding, soluble, 1 NM_002305 Upregulated in prostate, colon,
and pancreatic cancer
1.52 Tumor necrosis factor receptor
NM_003842 Upregulated in renal cell
superfamily, member 10b
carcinoma
-1.61 Tumor necrosis factor receptor
NM_003823 Amplified in Barrett's
superfamily, member 6b, decoy
adenocarcinoma
41
[54]
[55,56]
[57]
Oncogene/tu [58,59]
mour
suppressor
Oncogene
[60]
Oncogene
[61,62]
[63]
[64]
Tumour
suppressor
[65,66]
Tumour
suppressor
Oncogene
[67,68]
[69,70]
[71,72]
Tumour
suppressor
[73,74]
[75]
Immune response
IFI27
1.62
IFIT1
1.44
Transporter activity
FTH1
2.46
Interferon, alpha-inducible protein 27 NM_005532 Upregulated in squamous cell
carcinoma
Interferon-induced protein with
NM_001548
tetratricopeptide repeats 1
[64]
Ferritin, heavy polypeptide 1
NM_002032 Upregulated in breast cancer
[76]
PRNP
1.57
Prion protein (p27-30)
NM_000311 Upregulated in gastric cancer
[77]
LCN2
1.90
Lipocalin 2
NM_005564 Upregulated in pancreatic cancer
Signal transduction
ARHGAP19 -1.67 Rho GTPase activating protein 19
ARHGDIB
OPN3
PRKD2
1.34
RAGE
-1.49 Renal tumor antigen
RIT1
1.52
TGFBR2
-1.35 Transforming growth factor, 
receptor II
TOPK
FZD5
GDF15
GRN
Others
MNS1
Protein kinase D2
Ras-like without CAAX 1
[78,79]
Tumour
suppressor
Oncogene
[80]
Oncogene
[82,83]
Oncogene
[84]
Tumour
suppressor
Oncogene
[85,86]
NM_032900
-2.13 Rho GDP dissociation inhibitor (GDI) NM_001175 Downregulated in bladder cancer
beta
-1.82 AXL receptor tyrosine kinase
NM_001699 Overexpressed in lung and breast
cancers
-1.56 T-LAK cell-originated protein kinase NM_018492 Upregulated in Burkitt's
lymphoma
1.68 Chromosome 2 open reading frame 31 NM_030804 Upregulated in renal cell
carcinoma
1.41 Growth differentiation factor 15
NM_004864 Upregulated in uveal melanoma
and prostate cancer
1.39 Granulin
NM_002087 Upregulated in breast, ovarian,
and renal cancers
-1.45 Opsin 3 (encephalopsin, panopsin)
NM_014322
AXL
Tumour
suppressor
[81]
[87,88]
NM_016457 Downregulated in lymphoma
[89]
NM_014226 Upregulated in bladder and renal
cell carcinoma, melanoma
NM_006912 Amplified in hepatocellular
carcinoma
D50683
Mutated in colon cancer
[90]
TncRNA
-1.85 Meiosis-specific nuclear structural
NM_018365
protein 1
1.46 Trophoblast-derived noncoding RNA AU134977
KIAA0746
1.54
KIAA0746 protein
NM_015187
WDR48
1.65
WD repeat endosomal protein
NM_020839
AA721025
2.26
Unknown
AA721025
BE503392
1.57
Unknown
BE503392
CDCCR
1.46
AF056433
FLJ10901
1.68
Clone FBD3 Cri-du-chat critical
region mRNA
Hypothetical protein FLJ10901
NM_018265
42
Tumour
suppressor
Tumour
suppressor
[91,92]
[93]
References for Supplementary Table 1
1. Baker H, Patel V, Molinolo AA et al. Proteome-wide analysis of head and neck squamous
cell carcinomas using laser-capture microdissection and tandem mass spectrometry. Oral
Oncol 2005;41:183-199.
2. Luo A, Kong J, Hu G et al. Discovery of Ca2+-relevant and differentiation-associated
genes downregulated in esophageal squamous cell carcinoma using cDNA microarray.
Oncogene 2004;23:1291-1299.
3. Hippo Y, Yashiro M, Ishii M et al. Differential gene expression profiles of scirrhous
gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer
Res 2001;61:889-895.
4. Blumenthal RD, Hansen HJ, Goldenberg DM. Inhibition of adhesion, invasion, and
metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5
(Carcinoembryonic Antigen). Cancer Res 2005;65:8809-8817.
5. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. CEACAM6 gene silencing
impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma
cells. Oncogene 2004;23:465-473.
6. Gold JS, Reynolds AB, Rimm DL. Loss of p120ctn in human colorectal cancer predicts
metastasis and poor survival. Cancer Lett 1998;132:193-201.
7. Shibata T, Kokubu A, Sekine S, Kanai Y, Hirohashi S. Cytoplasmic p120ctn regulates the
invasive phenotypes of E-cadherin-deficient breast cancer. Am J Pathol 2004;164:22692278.
8. Koshikawa K, Osada H, Kozaki K et al. Significant up-regulation of a novel gene, CLCP1,
in a highly metastatic lung cancer subline as well as in lung cancers in vivo. Oncogene
2002;21:2822-2828.
9. Carl P, Kwok CH, Manderson G, Speicher DW, Discher DE. Forced unfolding modulated
by disulfide bonds in the Ig domains of a cell adhesion molecule. Proc Natl Acad Sci U S
A 2001;98:1565-1570.
10. Shih LM, Hsu MY, Palazzo JP, Herlyn M. The cell-cell adhesion receptor Mel-CAM acts
as a tumor suppressor in breast carcinoma. Am J Pathol 1997;151:745-751.
11. Kwaepila N, Burns G, Leong AS. Immunohistological localisation of human FAT1
(hFAT) protein in 326 breast cancers. Does this adhesion molecule have a role in
pathogenesis? Pathology 2006;38:125-131.
12. Tuszynski GP, Smith M, Rothman VL et al. Thrombospondin levels in patients with
malignancy. Thromb Haemost 1992;67:607-611.
13. Shafiee A, Penn JS, Krutzsch HC, Inman JK, Roberts DD, Blake DA. Inhibition of retinal
angiogenesis by peptides derived from thrombospondin-1. Invest Ophthalmol Vis Sci
2000;41:2378-2388.
14. Zhu Y, Brannstrom M, Janson PO, Sundfeldt K. Differences in expression patterns of the
tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as
compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer
2006;118:1884-1891.
15. Lee SK, Moon J, Park SW, Song SY, Chung JB, Kang JK. Loss of the tight junction
protein claudin 4 correlates with histological growth-pattern and differentiation in
advanced gastric adenocarcinoma. Oncol Rep 2005;13:193-199.
16. Huang X, Godfrey TE, Gooding WE, McCarty KS, Jr., Gollin SM. Comprehensive
genome and transcriptome analysis of the 11q13 amplicon in human oral cancer and
synteny to the 7F5 amplicon in murine oral carcinoma. Genes Chromosomes Cancer
2006;45:1058-1069.
43
17. Ji J, Zhao L, Wang X et al. Differential expression of S100 gene family in human
esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2004;130:480-486.
18. Rogers MS, Foley MA, Crotty TB et al. Loss of immunoreactivity for human calmodulinlike protein is an early event in breast cancer development. Neoplasia 1999;1:220-225.
19. Ji Q, Chang L, VanDenBerg D, Stanczyk FZ, Stolz A. Selective reduction of AKR1C2 in
prostate cancer and its role in DHT metabolism. Prostate 2003;54:275-289.
20. Ji Q, Aoyama C, Nien YD et al. Selective loss of AKR1C1 and AKR1C2 in breast cancer
and their potential effect on progesterone signaling. Cancer Res 2004;64:7610-7617.
21. Lewis MJ, Wiebe JP, Heathcote JG. Expression of progesterone metabolizing enzyme
genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast
carcinoma. BMC Cancer 2004;4:27.
22. Hughes SJ, Glover TW, Zhu XX et al. A novel amplicon at 8p22-23 results in
overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci U S A
1998;95:12410-12415.
23. Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM. Overexpression of cytochrome P450
1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme
compartmentation may contribute to carcinogenesis. Cancer Res 2005;65:3726-3734.
24. Strassburg CP, Manns MP, Tukey RH. Differential down-regulation of the UDPglucuronosyltransferase 1A locus is an early event in human liver and biliary cancer.
Cancer Res 1997;57:2979-2985.
25. True L, Coleman I, Hawley S et al. A molecular correlate to the Gleason grading system
for prostate adenocarcinoma. Proc Natl Acad Sci U S A 2006;103:10991-10996.
26. Moore S, Knudsen B, True LD et al. Loss of stearoyl-CoA desaturase expression is a
frequent event in prostate carcinoma. Int J Cancer 2005;114:563-571.
27. Folgueira MA, Brentani H, Katayama ML et al. Gene expression profiling of clinical
stages II and III breast cancer. Braz J Med Biol Res 2006;39:1101-1113.
28. Obama K, Ura K, Satoh S, Nakamura Y, Furukawa Y. Up-regulation of PSF2, a member
of the GINS multiprotein complex, in intrahepatic cholangiocarcinoma. Oncol Rep
2005;14:701-706.
29. Dillon BJ, Prieto VG, Curley SA et al. Incidence and distribution of argininosuccinate
synthetase deficiency in human cancers: a method for identifying cancers sensitive to
arginine deprivation. Cancer 2004;100:826-833.
30. Angrand PO, Apiou F, Stewart AF, Dutrillaux B, Losson R, Chambon P. NSD3, a new
SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell
lines. Genomics 2001;74:79-88.
31. Hudlebusch HR, Theilgaard-Monch K, Lodahl M, Johnsen HE, Rasmussen T.
Identification of ID-1 as a potential target gene of MMSET in multiple myeloma. Br J
Haematol 2005;130:700-708.
32. Regalo G, Canedo P, Suriano G et al. C/EBPbeta is over-expressed in gastric
carcinogenesis and is associated with COX-2 expression. J Pathol 2006;210:398-404.
33. Li W, Kessler P, Yeger H et al. A gene expression signature for relapse of primary wilms
tumors. Cancer Res 2005;65:2592-2601.
34. Ferrari N, Palmisano GL, Paleari L et al. DLX genes as targets of ALL-1: DLX 2,3,4
down-regulation in t(4;11) acute lymphoblastic leukemias. J Leukoc Biol 2003;74:302305.
35. Yang H, Ma G, Lin CH, Orr M, Wathelet MG. Mechanism for transcriptional synergy
between interferon regulatory factor (IRF)-3 and IRF-7 in activation of the interferon-beta
gene promoter. Eur J Biochem 2004;271:3693-3703.
44
36. Lu PJ, Sundquist K, Baeckstrom D et al. A novel gene (PLU-1) containing highly
conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast
cancer. J Biol Chem 1999;274:15633-15645.
37. Hanissian SH, Teng B, Akbar U et al. Regulation of myeloid leukemia factor-1 interacting
protein (MLF1IP) expression in glioblastoma. Brain Res 2005;1047:56-64.
38. Golay J, Luppi M, Songia S et al. Expression of A-myb, but not c-myb and B-myb, is
restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of
chronic lymphocytic leukemias. Blood 1996;87:1900-1911.
39. Joseph P, Muchnok T, Ong T. Gene expression profile in BALB/c-3T3 cells transformed
with beryllium sulfate. Mol Carcinog 2001;32:28-35.
40. Daniels T, Zhang J, Gutierrez I et al. Antinuclear autoantibodies in prostate cancer:
immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and
cleaved during apoptosis. Prostate 2005;62:14-26.
41. Dammann R, Strunnikova M, Schagdarsurengin U et al. CpG island methylation and
expression of tumour-associated genes in lung carcinoma. Eur J Cancer 2005;41:12231236.
42. Xi S, Dyer KF, Kimak M et al. Decreased STAT1 expression by promoter methylation in
squamous cell carcinogenesis. J Natl Cancer Inst 2006;98:181-189.
43. Lui VW, Boehm AL, Koppikar P et al. Antiproliferative Mechanisms of a Transcription
Factor Decoy Targeting STAT3: the Role of STAT1. Mol Pharmacol 2007;71:1435-1443.
44. Liu Y, Gao L, Gelman IH. SSeCKS/Gravin/AKAP12 attenuates expression of
proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis.
BMC Cancer 2006;6:105.
45. Malentacchi F, Marzocchini R, Gelmini S et al. Up-regulated expression of low molecular
weight protein tyrosine phosphatases in different human cancers. Biochem Biophys Res
Commun 2005;334:875-883.
46. Midorikawa Y, Tsutsumi S, Taniguchi H et al. Identification of genes associated with
dedifferentiation of hepatocellular carcinoma with expression profiling analysis. Jpn J
Cancer Res 2002;93:636-643.
47. Gstaiger M, Jordan R, Lim M et al. Skp2 is oncogenic and overexpressed in human
cancers. Proc Natl Acad Sci U S A 2001;98:5043-5048.
48. Satoh E, Mabuchi T, Satoh H, Asahara T, Nukui H, Naganuma H. Reduced expression of
the transporter associated with antigen processing 1 molecule in malignant glioma cells,
and its restoration by interferon-gamma and -beta. J Neurosurg 2006;104:264-271.
49. Sumiyoshi K, Baba S, Sakaguchi S, Urano T, Takada Y, Takada A. Increase in levels of
plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer:
possible roles in tumor progression and metastasis. Thromb Res 1991;63:59-71.
50. Kerr J, Leary JA, Hurst T et al. Allelic loss on chromosome 7q in ovarian
adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus.
Oncogene 1996;13:1815-1818.
51. Gleeson N, Gonsalves R, Bonnar J. The plasminogen activator urokinase and its inhibitor
PAI-2 in endometrial cancer. Gynecol Oncol 1992;47:58-61.
52. Maemondo M, Saijo Y, Narumi K et al. Gene therapy with secretory leukoprotease
inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung
cancer. Cancer Res 2004;64:4611-4620.
53. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K. Use of serum
secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian
cancer diagnosis. Gynecol Oncol 2005;96:516-519.
54. Robinson PA, Markham AF, Schalkwijk J, High AS. Increased elafin expression in cystic,
dysplastic and neoplastic oral tissues. J Oral Pathol Med 1996;25:135-139.
45
55. Turton NJ, Judah DJ, Riley J et al. Gene expression and amplification in breast carcinoma
cells with intrinsic and acquired doxorubicin resistance. Oncogene 2001;20:1300-1306.
56. Yamashita K, Mori M, Kataoka A, Inoue H, Sugimachi K. The clinical significance of
MMP-1 expression in oesophageal carcinoma. Br J Cancer 2001;84:276-282.
57. Lu Y, Lemon W, Liu PY et al. A gene expression signature predicts survival of patients
with stage I non-small cell lung cancer. PLoS Med 2006;3:e467.
58. Evron E, Umbricht CB, Korz D et al. Loss of cyclin D2 expression in the majority of
breast cancers is associated with promoter hypermethylation. Cancer Res 2001;61:27822787.
59. Lewis CM, Cler LR, Bu DW et al. Promoter hypermethylation in benign breast epithelium
in relation to predicted breast cancer risk. Clin Cancer Res 2005;11:166-172.
60. Ma Y, Lin D, Sun W et al. Expression of targeting protein for xklp2 associated with both
malignant transformation of respiratory epithelium and progression of squamous cell lung
cancer. Clin Cancer Res 2006;12:1121-1127.
61. Fujii T, Nomoto S, Koshikawa K et al. Overexpression of pituitary tumor transforming
gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology
2006;43:1267-1275.
62. Winnepenninckx V, Debiec-Rychter M, Belien JA et al. Expression and possible role of
hPTTG1/securin in cutaneous malignant melanoma. Mod Pathol 2006;19:1170-1180.
63. Park PC, Taylor MD, Mainprize TG et al. Transcriptional profiling of medulloblastoma in
children. J Neurosurg 2003;99:534-541.
64. Suomela S, Cao L, Bowcock A, Saarialho-Kere U. Interferon alpha-inducible protein 27
(IFI27) is upregulated in psoriatic skin and certain epithelial cancers. J Invest Dermatol
2004;122:717-721.
65. Mohr S, Bottin MC, Lannes B et al. Microdissection, mRNA amplification and
microarray: a study of pleural mesothelial and malignant mesothelioma cells. Biochimie
2004;86:13-19.
66. Ruan W, Xu E, Xu F et al. IGFBP7 Plays a Potential Tumor Suppressor Role in
Colorectal Carcinogenesis. Cancer Biol Ther 2007;6:354-359.
67. Sampath D, Winneker RC, Zhang Z. Cyr61, a member of the CCN family, is required for
MCF-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human
breast cancer. Endocrinology 2001;142:2540-2548.
68. Chien W, Yin D, Gui D et al. Suppression of cell proliferation and signaling transduction
by connective tissue growth factor in non-small cell lung cancer cells. Mol Cancer Res
2006;4:591-598.
69. Koyamatsu Y, Yokoyama M, Nakao Y et al. A comparative analysis of human
papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal,
and vulvar carcinomas. Gynecol Oncol 2003;90:547-551.
70. Botto Micca F, Coda R, Giordano F, Bona A, Bossotti M, Benedetto C. [Squamous
carcinoma of the gallbladder. Anatomo-clinical study of a case with reference to oncogene
expression]. Pathologica 1997;89:77-80.
71. van den Brule FA, Waltregny D, Castronovo V. Increased expression of galectin-1 in
carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J
Pathol 2001;193:80-87.
72. Berberat PO, Friess H, Wang L et al. Comparative analysis of galectins in primary tumors
and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 2001;49:539549.
73. Diegmann J, Tomiuk S, Sanjmyatav J, Junker K, Hindermann W, von Eggeling F.
Comparative transcriptional and functional profiling of clear cell and papillary renal cell
carcinoma. Int J Mol Med 2006;18:395-403.
46
74. Adams J, Cuthbert-Heavens D, Bass S, Knowles MA. Infrequent mutation of TRAIL
receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss
of heterozygosity. Cancer Lett 2005;220:137-144.
75. Albrecht B, Hausmann M, Zitzelsberger H et al. Array-based comparative genomic
hybridization for the detection of DNA sequence copy number changes in Barrett's
adenocarcinoma. J Pathol 2004;203:780-788.
76. Moroz C, Traub L, Maymon R, Zahalka MA. PLIF, a novel human ferritin subunit from
placenta with immunosuppressive activity. J Biol Chem 2002;277:12901-12905.
77. Pan Y, Zhao L, Liang J et al. Cellular prion protein promotes invasion and metastasis of
gastric cancer. Faseb J 2006;20:1886-1888.
78. Laurell H, Bouisson M, Berthelemy P et al. Identification of biomarkers of human
pancreatic adenocarcinomas by expression profiling and validation with gene expression
analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J
Gastroenterol 2006;12:3344-3351.
79. Hanai J, Mammoto T, Seth P et al. Lipocalin 2 diminishes invasiveness and metastasis of
Ras-transformed cells. J Biol Chem 2005;280:13641-13647.
80. Titus B, Frierson HF, Jr., Conaway M et al. Endothelin axis is a target of the lung
metastasis suppressor gene RhoGDI2. Cancer Res 2005;65:7320-7327.
81. Chung BI, Malkowicz SB, Nguyen TB, Libertino JA, McGarvey TW. Expression of the
proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol 2003;22:533-540.
82. Simons-Evelyn M, Bailey-Dell K, Toretsky JA et al. PBK/TOPK is a novel mitotic kinase
which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells.
Blood Cells Mol Dis 2001;27:825-829.
83. Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PDZ-binding kinase/T-LAK celloriginated protein kinase, a putative cancer/testis antigen with an oncogenic activity in
breast cancer. Cancer Res 2006;66:9186-9195.
84. Janssens N, Andries L, Janicot M, Perera T, Bakker A. Alteration of frizzled expression in
renal cell carcinoma. Tumour Biol 2004;25:161-171.
85. Folberg R, Arbieva Z, Moses J et al. Tumor cell plasticity in uveal melanoma:
microenvironment directed dampening of the invasive and metastatic genotype and
phenotype accompanies the generation of vasculogenic mimicry patterns. Am J Pathol
2006;169:1376-1389.
86. Martinez JM, Sali T, Okazaki R et al. Drug-induced expression of nonsteroidal antiinflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived
factor, a putative tumor suppressor, inhibits tumor growth. J Pharmacol Exp Ther
2006;318:899-906.
87. He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth
factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med 2003;81:600-612.
88. Tangkeangsirisin W, Serrero G. PC cell-derived growth factor (PCDGF/GP88,
progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer
cells. Carcinogenesis 2004;25:1587-1592.
89. Kovalevska LM, Yurchenko OV, Shlapatska LM et al. Immunohistochemical studies of
protein kinase D (PKD) 2 expression in malignant human lymphomas. Exp Oncol
2006;28:225-230.
90. Gaugler B, Brouwenstijn N, Vantomme V et al. A new gene coding for an antigen
recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.
Immunogenetics 1996;44:323-330.
91. Li JT, Liu W, Kuang ZH et al. [Amplification of RIT1 in hepatocellular carcinoma and its
clinical significance]. Ai Zheng 2003;22:695-699.
47
92. Wakabayashi Y, Inoue J, Takahashi Y et al. Homozygous deletions and point mutations of
the Rit1/Bcl11b gene in gamma-ray induced mouse thymic lymphomas. Biochem Biophys
Res Commun 2003;301:598-603.
93. Westbrook TF, Martin ES, Schlabach MR et al. A genetic screen for candidate tumor
suppressors identifies REST. Cell 2005;121:837-848.
48